



NEWS RELEASE

# CRINETICS PHARMACEUTICALS TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON NOVEMBER 12, 2024

2024-10-16

SAN DIEGO – October 16, 2024 – **Crinetics Pharmaceuticals, Inc.** (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Tuesday, November 12th @ 4:30 PM ET

Domestic: 1-800-579-2543

International: 1-785-424-1789

Conference ID: CRNXQ3

Participants can use the dial-in numbers above OR access the call via live webcast on the **Events section** of the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or register at least 15 minutes prior to scheduled start of the call.

The webcast will be archived on the Investor Relations sections of [www.crinetics.com](http://www.crinetics.com).

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead



development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the company's drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

---

Investors:

Gayathri Diwakar

Head of Investor Relations

**[gdiwakar@crinetics.com](mailto:gdiwakar@crinetics.com)**

**(858) 345-6340**

Media:

Natalie Badillo

Head of Corporate Communications

**[nbadillo@crinetics.com](mailto:nbadillo@crinetics.com)**

**(858) 345-6075**

Source: Crinetics Pharmaceuticals, Inc.